# Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria

> **NCT00421109** · PHASE3 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 522 (actual)

## Conditions studied

- Urticaria

## Interventions

- **DRUG:** Bilastine
- **DRUG:** Levocetirizine
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00421109
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-07
- **Primary completion:** 2007-07
- **Final completion:** 2007-07
- **Target enrollment:** 522 (ACTUAL)
- **Last updated:** 2012-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00421109

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00421109, "Efficacy Study for the Symptomatic Treatment of Chronic Idiopathic Urticaria". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00421109. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*